CTLA4 and melanoma: For several malignancies, such as melanoma and non small-cell lung cancer, long-lasting durable responses have been achieved with CTLA-4 inhibitors such as ipilimumab [11] and PD-1 inhibitors such as pembrolizumab [12,13,14].